Avodart Online
Avodart (dutasteride) is a pill for the treatment of benign prostatic hyperplasia. Treatment and prevention of progression of benign prostatic hyperplasia by reducing prostate size, reduce the severity of symptoms, improve urinary flow, reduce the risk of acute urinary retention and need for surgical intervention. In combination with tamsulosin is the treatment and prevention of progression of benign prostatic hyperplasia by reducing prostate size, reduce the severity of symptoms and improve urinary flow.
Avodart can be given as monotherapy or in combination with α-receptor blocker tamsulosin (0.4 mg). The recommended dose is 1 capsule Avodart (0.5 mg) per day by mouth. Capsule swallowed whole, do not open and do not chew, because when in contact with the contents of the capsule may irritation of oral mucosa and pharynx. Avodart can be taken regardless of meals. Dutasteride can be absorbed through the skin, so women and children should avoid contact with leaky capsules. If fluid from the capsule gets on the skin, it should immediately wash with soap and water.
The influence of hepatic insufficiency on the pharmacokinetics of dutasteride is not known. Dutasteride is extensively metabolized, and its half-life of 3-5 weeks, a drug used with caution in liver disease. The effect on prostate is specific antigen (PSA) and prostate cancer. Before treatment dutasteride and periodically during treatment should be performed digital rectal examination of the patient and other studies to detect prostate cancer. The concentration of PSA is an important component of a screening method for detecting prostate cancer. Typically, the concentration of PSA in the blood plasma of 4 ng / mL (Hybritech) requires further examination and biopsy of prostate.
Also note that the baseline PSA ≤ 4 ng / ml in patients treated with dutasteride does not preclude the diagnosis of their prostate cancer. Avodart treatment can reduce the level of PSA in the blood plasma in benign prostatic hyperplasia by approximately 50% after 6 months even in the presence of prostate cancer. Given the pharmacokinetic and pharmacodynamic properties that dutasteride does not affect the reaction rate while operating a vehicle or operating machinery. The study of the interaction is of dutasteride with tamsulosin, terazotsinom, warfarin, digoxin and kolestiraminom. Clinically significant interactions have been identified. Although specific studies on the interactions with other drugs have not performed, about 90% of all patients in clinical trials of dutasteride received other concomitant therapy. No specific antidote, so in case of a possible overdose of being symptomatic therapy.
